Evidence map›Paper›PMID 30373528›Full record

ArticleBMC infectious diseases2018

Quality control implementation for universal characterization of DNA and RNA viruses in clinical respiratory samples using single metagenomic next-generation sequencing workflow.

A Bal, M Pichon, C Picard, J S Casalegno, M Valette, I Schuffenecker, L Billard, S Vallet, G Vilchez, V Cheynet and 7 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. RAPIDViruses · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

A BalLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
M PichonLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
C PicardUnité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.
J S CasalegnoLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
M ValetteLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
I SchuffeneckerLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
L BillardINSERM UMR1078 "Génétique, Génomique Fonctionnelle et Biotechnologies", Axe Microbiota, Univ Brest, Brest, France.
S ValletINSERM UMR1078 "Génétique, Génomique Fonctionnelle et Biotechnologies", Axe Microbiota, Univ Brest, Brest, France.
G VilchezLaboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
V CheynetLaboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
G OriolLaboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
S Trouillet-AssantLaboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
Y GilletHospices Civils de Lyon, Urgences pédiatriques, Hôpital Femme Mère Enfant, Bron, France.
B LinaLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
K Brengel-PesceLaboratoire Commun de Recherche HCL-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
F MorfinLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France.
L JossetLaboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France. laurence.josset@chu-lyon.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, metagenomic Next-Generation Sequencing (mNGS) has increasingly been used for an accurate assumption-free virological diagnosis. However, the systematic workflow evaluation on clinical respiratory samples and implementation of quality controls (QCs) is still lacking.

methodsA total of 3 QCs were implemented and processed through the whole mNGS workflow: a no-template-control to evaluate contamination issues during the process; an internal and an external QC to check the integrity of the reagents, equipment, the presence of inhibitors, and to allow the validation of results for each sample. The workflow was then evaluated on 37 clinical respiratory samples from patients with acute respiratory infections previously tested for a broad panel of viruses using semi-quantitative real-time PCR assays (28 positive samples including 6 multiple viral infections; 9 negative samples). Selected specimens included nasopharyngeal swabs (n = 20), aspirates (n = 10), or sputums (n = 7).

resultsThe optimal spiking level of the internal QC was first determined in order to be sufficiently detected without overconsumption of sequencing reads. According to QC validation criteria, mNGS results were validated for 34/37 selected samples. For valid samples, viral genotypes were accurately determined for 36/36 viruses detected with PCR (viral genome coverage ranged from 0.6 to 100%, median = 67.7%). This mNGS workflow allowed the detection of DNA and RNA viruses up to a semi-quantitative PCR Ct value of 36. The six multiple viral infections involving 2 to 4 viruses were also fully characterized. A strong correlation between results of mNGS and real-time PCR was obtained for each type of viral genome (R

conclusionsAlthough the potential of mNGS technology is very promising, further evaluation studies are urgently needed for its routine clinical use within a reasonable timeframe. The approach described herein is crucial to bring standardization and to ensure the quality of the generated sequences in clinical setting. We provide an easy-to-use single protocol successfully evaluated for the characterization of a broad and representative panel of DNA and RNA respiratory viruses in various types of clinical samples.

Indexed as

DNA, ViralDNA VirusesHigh-Throughput Nucleotide SequencingHumansMetagenomicsQuality ControlReal-Time Polymerase Chain ReactionRespiratory Tract InfectionsRNA, ViralRNA VirusesDNA, ViralRNA, ViralClinical virologyNext-generation sequencingQuality controlRespiratory virusesViral metagenomics

Identifiers

PMID30373528
PMCPMC6206636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.